The dynamics comparing the two treatment routes were consistent for CD107a expression and IFN-γ+CD107a+ double-positive cells, with i.v. showing higher frequencies than i.t. Furthermore, an additional experiment addressed whether the presence of an existing tumor affects the VSV-GP-specific CD8+ T cell immunity after i.v. virus treatment in terms of magnitude and epitope distribution. The gene discussed is LAMP1; the disease is neoplasm.